ProBioGen AG
Andrea Naujoks has a diverse work experience spanning various roles and companies. Andrea began their career as a Student Research Assistant at TU Berlin from July 2007 to February 2009. Andrea then worked as a Diploma Student and Trainee at the Robert Koch Institute from August 2009 to September 2010. Andrea served as a Researcher at Charité from May 2011 to April 2015. Andrea then joined Minerva Analytix GmbH as a Technical Director, responsible for microbiological quality control and method validation for the pharmaceutical industry, from July 2015 to September 2016. Andrea's latest role is at ProBioGen AG, where they started in September 2016 as the Deputy Head of Quality Control, involved in project management and the release of GMP raw materials, cell banks, and pharmaceutical drug substances. In January 2019, they were promoted to Head of Microbiology at ProBioGen AG.
Andrea Naujoks began their education at Technische Universität Berlin in 2003. From 2003 to 2010, they pursued a degree in Biotechnology, earning a Dipl.-Ing. After completing their undergraduate studies, they continued their academic journey at the same institution. From 2011 to 2015, they obtained a Dr.-Ing. degree, but the field of study is not specified.
ProBioGen AG
ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines. Our additional new building houses 1000 L single-use bioreactor capacity to keep up with the ever-increasing demand from our clients. A second 1000 L single-use bioreactor is coming soon. With over 25 years of experience in animal cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end.